Skip to main content
Premium Trial:

Request an Annual Quote

Joseph Limber, John Keller, Belinda Seto, Marvin Tancer, Naseem Usman, Barry Polisky, Mark Egan, Patti Ketchner


Prometheus Laboratories has appointed Joseph Limber president and CEO, the company said this week. Limber, who will also become a director of the company, comes to Prometheus from Aclara BioSciences, where he was president and CEO.

Before joining Aclara, Limber served as president and COO at Praecis Pharmaceuticals, and before that he held senior business development and sales and marketing positions with Sequus Pharmaceuticals, Syntex, and Ciba-Geigy, Prometheus said.

Limber also served as interim CEO of Deltagen. He holds a BA from Duquesne University and serves on the board of Vitex, according to Prometheus.

DiaDexus has appointed John Keller to its board of directors, the company said this week. Keller currently serves as executive vice president and chief business officer of Incyte, which he joined in September 2003. Before then, Keller was with GlaxoSmithKline since its formation in 2001 — most recently as vice president of business development — and with SmithKline Beecham since 1987.

Keller received a BA in biology from Johns Hopkins University and a PhD in microbiology from Rutgers University, according to DiaDexus.

Belinda Seto has been named deputy director of the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health, the NIH said earlier this month.

Seto comes to the NIBIB from a nearly one-year term as acting deputy director for extramural research at the NIH, where she advised the NIH director on extramural policy and developed policies and procedures for extramural research.

Seto also previously served as deputy director of the office of extramural research and the director of the OER’s office of reports and analysis during a nine-year tenure at the OER.

She has worked at the NIH since 1974, after receiving her PhD in biochemistry from Purdue University, according to the NIBIB.

Marvin Tancer, vice president of operations and chief financial officer at Sirna Therapeutics, is leaving the company “to pursue other opportunities,” the company said last week.

Meanwhile, the Boulder, Colo.-based company is promoting five other executives, including Naseem Usman, current chief scientific officer and vice president of research and development, who will now be chief operating officer and senior vice president.

Usman joined the company in 1992 and was made vice president of R&D in 2000. Prior to that, he was a post-doctoral fellow and staff scientist at the MIT departments of chemistry and biology, according to Sirna.

Other executive promotions include that of Barry Polisky, who has been promoted from vice president of research to senior vice president of research; Chandra Vargeese, who was formerly director of chemistry and now will be vice president, chemistry; Mark Egan, who was formerly director of manufacturing and is now vice president, manufacturing; and Patti Ketchner, who was director of finance and corporate controller, and is now vice president and corporate controller, Sirna said.


Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.